Indico Health Communications published a newly published study in Nature Medicine evaluating atezolizumab alongside chemotherapy in early triple-negative breast cancer, finding that the treatment did not significantly improve event-free survival across the overall study population.
Public source
Publisher name
Public post
Not every Phase 3 result fits neatly into “success” or “failure”. A newly published Nature Medicine study evaluated atezolizumab alongside chemotherapy in early triple-n…
Company
Indico Health Communications
Indico partners with agencies delivering medical communications, medical publications and life sciences training
- Company size
- 2–10 employees
About Indico Health Communications
Indico supports life sciences agencies with the delivery of medical communications, medical publications and life sciences training projects. We help life sciences agencies protect their margins. As medical learning specialists we combine scientific excellence, learning experience design and digital solutions to help our partners deliver for their client organisations. Our expertise allow us to provide valuable support to life sciences agencies and fill the skills gaps. We are flexible to meet immediate ad hoc requests with our range of medical learning services. We provide consultancy and strategic insight to build long-term, reliable partnerships. Let us join you to streamline content development, enhance project management workflows and deliver the highest quality medical communications, publications and life sciences training.
See moreDiscover more
Similar signals
Similar public activity from other companies.
Research & Knowledge
Universitätsmedizin Frankfurt
Universitätsmedizin Frankfurt published an international Phase III study with 1550 patients examining the effect of Atezolizumab as an adjunct to chemotherapy for early triple-negative breast cancer.
Research & Knowledge
Community Health Media
Community Health Media published research by Dr. Sonya Reid and Dr. Shruti Singh examining how trastuzumab deruxtecan plus pertuzumab reshapes first-line treatment decisions for HER2+ breast cancer patients.
Research & Knowledge
Elion Medical Communications
Elion Medical Communications reported that Moderna and Merck announced positive phase 3 results for intismeran autogene, an individualised mRNA cancer therapy, in patients with resected, high-risk melanoma.
Research & Knowledge
AACR Journals
AACR Journals published new research in Cancer Research Communications showing that tumor-associated platelets suppress T-cell function and promote immune evasion in triple-negative breast cancer via the P-selectin/ P-selectin glycoprotein ligand-1 pathway.
Research & Knowledge
intoDNA